Saldia A, Olson SH, Nunes P, et al. - Through a prospective study conducted within the Pancreatic Tumor Registry at a major cancer center on 83 high risk individuals (HRIs) with ≥ 1 first-degree relative with pancreatic ductal adenocarcinoma (PDAC), researchers assessed whether results of surveillance for PDAC in HRI varied between those with and without a pathogenic BRCA1/2 mutation. A total of 48 of 83 had a mutation in BRCA1/2 and 35 did not. Overall, 16 of 48 and 13 of 35 BRCA1/2-positive and BRCA1/2-negative participants, respectively, had pancreatic abnormalities on imaging and in each group, all but one finding was an intraductal papillary mucinous neoplasm. Among those with pathogenic mutations but weaker family history, outcomes were comparable, ie, 7 of 18 with pancreatic abnormalities. Outcomes of surveillance for pancreatic abnormalities on imaging were comparable irrespective of BRCA1/2 mutation status. While the outcomes from this small study require validation in other studies, at present, there was not seemingly elevated yield from targeting individuals with BRCA1/2 mutations for surveillance.